Publications by authors named "F Mitjavila"

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by the presence of autoantibodies against factor VIII (FVIII). As with other autoimmune diseases, its etiology is complex and its genetic basis is unknown. The aim of this study was to identify the immunogenetic background that predisposes individuals to AHA.

View Article and Find Full Text PDF

: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). : The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy.

View Article and Find Full Text PDF

C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP.

View Article and Find Full Text PDF
Article Synopsis
  • Granulomatous mastitis (GM) is an inflammatory condition in breast tissue that can sometimes be associated with erythema nodosum (EN), which causes red, painful nodules on the skin, mainly in the legs.
  • A study reviewing cases from 1995 to 2020 found that out of 42 diagnosed women, 11.9% had GM associated with EN, and those with EN were diagnosed significantly earlier than those with GM alone.
  • The presence of EN also correlated with a higher likelihood of ulceration in GM cases, indicating that EN could be a helpful indicator for faster diagnosis of GM, which can mimic breast cancer symptoms.
View Article and Find Full Text PDF

Severe lung injury is triggered by both the SARS-CoV-2 infection and the subsequent host-immune response in some COVID-19 patients. We conducted a randomized, single-center, open-label, phase II trial with the aim to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) vs. SoC alone, in hospitalized patients with severe COVID-19.

View Article and Find Full Text PDF